Developer docs
API playgroundTry for free, no card

Search company profiles

CINPHARM SA

Full company profile

uuid02lxb6s

Namestring
CINPHARM SA
Legal namestring
Compagnie Industrielle Pharmaceutique (CINPHARM)
Websiteurl
cinpharm.net
Company typeenum
Private
Founded yearint
2006
Descriptiontext

CINPHARM SA (Compagnie Industrielle Pharmaceutique) is a privately held pharmaceutical manufacturer headquartered in Douala, Cameroon, and a wholly-owned subsidiary of the CADYST-Invest industrial group since 2007. The company operates a single integrated manufacturing complex organized into three segregated production units compliant with WHO Good Manufacturing Practices: a general formulation unit producing tablets, capsules, dry syrups, and liquid syrups; a dedicated beta-lactam antibiotics facility with isolated personnel, water, air handling, and quality control; and a large-volume parenteral solutions unit running BFS (Blow-Fill-Seal) technology. Annual installed capacities total roughly 1.2 billion tablets, 56 million capsules, 3 million dry syrups, 10 million liquid syrups, 280 million beta-lactam tablets, and 10 million IV flasks at 250ml and 500ml formats, supporting a portfolio of approximately 60 molecules focused on malaria, HIV/AIDS, tuberculosis and other essential medicines for African public health.

The technical backbone includes 59 HEPA-filtered air handling units, multi-technology pharmaceutical water purification with 44 sampling points, and two quality control laboratories built to 21 CFR Part 11 standards. Two hundred meters of environmental protection infrastructure — including a 30m boiler chimney, 59 air filtration centers, and a dedicated pharmaceutical wastewater treatment unit — support regulatory compliance. The facility was inaugurated on April 8, 2010 by the Minister of Health on behalf of the Prime Minister, marking Cameroon's first pharmaceutical laboratory fully compliant with international standards. Technology transfer and training have been delivered by India's Cipla, with capacity-building support from UNIDO and financial backing from Germany's DEG.

CINPHARM generates revenue through two streams: direct manufacturing and sale of generic essential medicines (médicaments essentiels génériques) at a stated target of less than $1 per patient per day, and a licensed manufacturing partnership platform open to international laboratories seeking African-market production under technology transfer. Primary customers are African healthcare systems, government health programs (notably the Cameroon Ministry of Health, for which CINPHARM serves as a public health policy implementation tool), and international pharmaceutical laboratories. The company is led by President and Director General Célestin Tawamba and operates as the reference pharmaceutical laboratory in Sub-Saharan Africa by its own positioning.

Short descriptiontext

CINPHARM SA is a Cameroonian pharmaceutical manufacturer producing generic essential medicines (tablets, capsules, syrups, beta-lactam antibiotics, and large-volume IV solutions) for African public health programs, governments, and licensed-manufacturing partners from a WHO GMP-compliant facility in Douala.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersDouala, Cameroon
HQ citystring
Douala
HQ countrystring
Cameroon
HQ regionstring
Africa
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceutical manufacturing, essential medicines production, beta-lactam antibiotics, large volume parenteral solutions, contract pharmaceutical manufacturing
Industry4 codes
PRIMARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAGAGAL
GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAIAJAF
Government & Public-Sector Pharmaceutical Supply (Tender/Prime Vendor)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Generic Pharmaceutical Manufacturing
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Generic Pharmaceutical Products
TypeOne Time License
Description

Manufacturing and sale of generic essential medicines (médicaments essentiels génériques - MEG) targeting malaria, HIV/AIDS, and tuberculosis treatment. Production covers approximately 60 molecules across various dosage forms including tablets, capsules, syrups, and large volume solutions.

cinpharm.net
2Licensed Manufacturing Partnerships
TypeLicensing Royalties
Description

Open platform for partnerships with international laboratories desiring to manufacture medications under license, offering technology transfer and manufacturing capabilities

cinpharm.net
Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

CINPHARM manufactures generic essential medicines (médicaments essentiels génériques — MEG) targeting malaria, HIV/AIDS, and tuberculosis through three distinct WHO GMP-compliant production units: Formulation Générale (tablets, capsules, syrups), Antibiotiques Bétalactamines (dedicated beta-lactam facility), and Solutés massifs (large volume IV solutions via BFS technology). Beyond manufacturing its own ~60-molecule portfolio, the company operates as an open platform offering technology transfer and licensed contract manufacturing for international pharmaceutical laboratories.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

CINPHARM SA operates a pharmaceutical manufacturing site in Douala, Cameroon with three distinct production units: Formulation Générale (tablets, capsules, syrups), Antibiotiques Bétalactamines (dedicated beta-lactam antibiotics facility), and Solutés massifs (large volume IV solutions using BFS technology). The company produces generic essential medicines (MEG) and offers itself as an open platform for licensing partnerships with other pharmaceutical laboratories. The site includes two quality control laboratories (21 CFR/2 compliant) and an environmental protection unit.

Product and service5 records
1Formulation Générale (General Formulation Unit)
CategorySolid Oral Dosage Pharmaceutical Manufacturing
Description

General formulation production unit equipped to produce solid oral dosage forms including tablets (1,200 million units/year), dry syrups (3 million units/year), and liquid syrups (10 million units/year). Features 2 granulation rooms (one with explosion-proof system) and 2 compression rooms with high-capacity rotary tablet presses. Designed for WHO GMP compliance and serves as the primary unit for general therapeutic generic medicines.

2Antibiotiques Bétalactamines (Beta-lactam Antibiotics Unit)
CategoryBeta-lactam Antibiotic Manufacturing
Description

Dedicated beta-lactam antibiotic production unit with fully segregated facilities, equipment, personnel, water treatment, air handling, and a dedicated quality control laboratory. Production capacity of 280 million tablets and 56 million capsules per year. Includes dedicated changing rooms with air shower exit system and special air treatment with water purification to prevent cross-contamination.

3Solutés massifs (Large Volume Parenteral Solutions Unit)
CategorySterile Large Volume Parenteral Manufacturing
Description

Large volume parenteral solutions (IV fluids) production unit with installed capacity of 10 million 250ml and 500ml flasks per year using BFS (Blow-Fill-Seal) technology with pharmaceutical grade B and A zone filling. Features stainless steel 316L tanks, 2-micron and 0.22-micron filtration, nitrogen pressure transfer, and autoclave sterilization for injectable-grade solutions.

4Médicaments Génériques (Generic Medicines Portfolio)
CategoryGeneric Essential Medicines
Description

Portfolio of approximately 60 pharmaceutical molecules producing a varied range of generic essential medicines (MEG) adapted to African public health challenges and emerging pandemics. Therapeutic focus areas include malaria, HIV/AIDS, and tuberculosis treatments, with products manufactured across all three CINPHARM production units in various dosage forms.

5Licensed Manufacturing Partnerships (Technology Transfer Platform)
CategoryContract Manufacturing / Technology Transfer Services
Description

Open partnership platform offering international pharmaceutical laboratories technology transfer and licensed manufacturing services using CINPHARM's GMP-compliant facilities and expertise. Designed to enable international partners to manufacture medications under license for African markets, leveraging CINPHARM's WHO GMP certification and quality infrastructure.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeOthersAnnounced on2007-01-01
Description

CADYST-Invest is the parent industrial group that acquired CINPHARM as a subsidiary in 2007. The group provided the vision and investment strength for establishing the pharmaceutical manufacturing facility in Cameroon.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

The United Nations Industrial Development Organization contributed to the training of CINPHARM's collaborators, supporting capacity building for pharmaceutical manufacturing expertise.

3Republic of Cameroon
Strategic tierCoreTypeStrategic or Co-development Partner
Description

The Cameroon government supported and facilitated CINPHARM's investment program. CINPHARM serves as an implementation tool for the government's public health policy.

cinpharm.net
Strategic tierCoreTypeTechnology or Integration
Description

Indian pharmaceutical company Cipla provides technology transfer and training to CINPHARM, enabling the development of pharmaceutical manufacturing capabilities.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

The scientific committee is sponsored by Pr Gentilini of the Fondation Chirac. Pr Gentilini served as President of the French Red Cross and General Delegate for access to quality medicines at Fondation Chirac.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global pharmaceutical major with significant African generics and vaccines presence via its Sanofi Global Health unit. Important adjacent incumbent shaping African essential medicines tenders and partnership opportunities relevant to CINPHARM's licensing model.

TypeBroad incumbent
Description

Indian global generic pharmaceutical manufacturer with significant emerging markets and Africa exposure across antimalarials, ARVs, and essential medicines. Comparable high-volume low-cost generic business model targeting African and other emerging market tenders.

TypeRegional player
Description

Nigeria-listed pharmaceutical manufacturer producing generic essential medicines across therapeutic categories with multiple production lines. Comparable as a West/Central African local generic manufacturer competing for similar public-sector and regional tenders.

TypeBroad incumbent
Description

Largest African pharmaceutical manufacturer, headquartered in South Africa, with broad generic essential medicines, ARVs, and sterile manufacturing capacity. Aspirational reference peer for CINPHARM's ambition to be the reference pharma lab in Sub-Saharan Africa.

TypeRegional player
Description

Nigerian pharmaceutical manufacturer with diversified generic essential medicines portfolio across tablets, capsules, syrups, and injectables. Regional West African peer with similar scale, multi-unit production, and public-sector tender focus.

TypeBroad incumbent
Description

Indian global generic pharmaceutical company with strong Africa-focused ARV and essential medicines franchise and WHO prequalifications. Closely mirrors CINPHARM's product focus and partnership-style business model.

TypeBroad incumbent
Description

Indian global generic pharmaceutical major and CINPHARM's explicit technology transfer partner. Cipla is the most directly comparable peer as a high-volume, low-cost generic manufacturer with deep Africa exposure — the very model CINPHARM emulates at smaller scale.

8Quality Chemical Industries Limited
TypeDirect peer
Description

Uganda-based WHO-prequalified generic pharmaceutical manufacturer, also established with Cipla technology transfer and donor-aligned product portfolio (including antimalarials and ARVs). CINPHARM's closest structural peer in East/Central Africa in terms of origin story, partnership model, and product focus.

TypeRegional player
Description

Kenyan pharmaceutical manufacturer producing generic essential medicines, antimalarials, and ARVs for East African markets. Regional African generic manufacturer with similar scale, product breadth, and WHO-aligned positioning as CINPHARM.

10Addis Pharmaceutical Factory
TypeRegional player
Description

Ethiopian state-affiliated generic pharmaceutical manufacturer producing essential medicines for domestic and export markets. Comparable as an African local generic manufacturer serving a domestic public health mandate with multiple production units.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CINPHARM SA

Generic Pharmaceutical Manufacturingcinpharm.net

CINPHARM SA is a Cameroonian pharmaceutical manufacturer producing generic essential medicines (tablets, capsules, syrups, beta-lactam antibiotics, and large-volume IV solutions) for African public health programs, governments, and licensed-manufacturing partners from a WHO GMP-compliant facility in Douala.

What CINPHARM SA does

CINPHARM SA (Compagnie Industrielle Pharmaceutique) is a privately held pharmaceutical manufacturer headquartered in Douala, Cameroon, and a wholly-owned subsidiary of the CADYST-Invest industrial group since 2007. The company operates a single integrated manufacturing complex organized into three segregated production units compliant with WHO Good Manufacturing Practices: a general formulation unit producing tablets, capsules, dry syrups, and liquid syrups; a dedicated beta-lactam antibiotics facility with isolated personnel, water, air handling, and quality control; and a large-volume parenteral solutions unit running BFS (Blow-Fill-Seal) technology. Annual installed capacities total roughly 1.2 billion tablets, 56 million capsules, 3 million dry syrups, 10 million liquid syrups, 280 million beta-lactam tablets, and 10 million IV flasks at 250ml and 500ml formats, supporting a portfolio of approximately 60 molecules focused on malaria, HIV/AIDS, tuberculosis and other essential medicines for African public health.

The technical backbone includes 59 HEPA-filtered air handling units, multi-technology pharmaceutical water purification with 44 sampling points, and two quality control laboratories built to 21 CFR Part 11 standards. Two hundred meters of environmental protection infrastructure — including a 30m boiler chimney, 59 air filtration centers, and a dedicated pharmaceutical wastewater treatment unit — support regulatory compliance. The facility was inaugurated on April 8, 2010 by the Minister of Health on behalf of the Prime Minister, marking Cameroon's first pharmaceutical laboratory fully compliant with international standards. Technology transfer and training have been delivered by India's Cipla, with capacity-building support from UNIDO and financial backing from Germany's DEG.

CINPHARM generates revenue through two streams: direct manufacturing and sale of generic essential medicines (médicaments essentiels génériques) at a stated target of less than $1 per patient per day, and a licensed manufacturing partnership platform open to international laboratories seeking African-market production under technology transfer. Primary customers are African healthcare systems, government health programs (notably the Cameroon Ministry of Health, for which CINPHARM serves as a public health policy implementation tool), and international pharmaceutical laboratories. The company is led by President and Director General Célestin Tawamba and operates as the reference pharmaceutical laboratory in Sub-Saharan Africa by its own positioning.

CINPHARM SA firmographics

Firmographics
Name
CINPHARM SA
Legal name
Compagnie Industrielle Pharmaceutique (CINPHARM)
Website
https://cinpharm.net
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
51–100 employees
Short description
CINPHARM SA is a Cameroonian pharmaceutical manufacturer producing generic essential medicines (tablets, capsules, syrups, beta-lactam antibiotics, and large-volume IV solutions) for African public health programs, governments, and licensed-manufacturing partners from a WHO GMP-compliant facility in Douala.
Ownership category
akta.pro rank

CINPHARM SA industry classification

Industry
Product category
Generic Pharmaceutical Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAGAGAL
GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAIAJAF
Government & Public-Sector Pharmaceutical Supply (Tender/Prime Vendor)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Generic pharmaceutical manufacturing
  • Essential medicines production
  • Beta-lactam antibiotics
  • Large volume parenteral solutions
  • Contract pharmaceutical manufacturing

Where CINPHARM SA is headquartered

Location

Headquarters

HQ city
Douala
HQ country
Cameroon
HQ region
Africa

Offices1 record

Markets served

CINPHARM SA business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain

Revenue model

  1. Generic Pharmaceutical Products: Manufacturing and sale of generic essential medicines (médicaments essentiels génériques - MEG) targeting malaria, HIV/AIDS, and tuberculosis treatment. Production covers approximately 60 molecules across various dosage forms including tablets, capsules, syrups, and large volume solutions.
  2. Licensed Manufacturing Partnerships: Open platform for partnerships with international laboratories desiring to manufacture medications under license, offering technology transfer and manufacturing capabilities

Go-to-market motion1 record

Distribution channels1 record

CINPHARM SA product offering

Product offering

Core offering

CINPHARM manufactures generic essential medicines (médicaments essentiels génériques — MEG) targeting malaria, HIV/AIDS, and tuberculosis through three distinct WHO GMP-compliant production units: Formulation Générale (tablets, capsules, syrups), Antibiotiques Bétalactamines (dedicated beta-lactam facility), and Solutés massifs (large volume IV solutions via BFS technology). Beyond manufacturing its own ~60-molecule portfolio, the company operates as an open platform offering technology transfer and licensed contract manufacturing for international pharmaceutical laboratories.

Product overview

CINPHARM SA operates a pharmaceutical manufacturing site in Douala, Cameroon with three distinct production units: Formulation Générale (tablets, capsules, syrups), Antibiotiques Bétalactamines (dedicated beta-lactam antibiotics facility), and Solutés massifs (large volume IV solutions using BFS technology). The company produces generic essential medicines (MEG) and offers itself as an open platform for licensing partnerships with other pharmaceutical laboratories. The site includes two quality control laboratories (21 CFR/2 compliant) and an environmental protection unit.

Differentiator

Problem solved

Functional benefit

Products and services

  • Formulation Générale (General Formulation Unit) General formulation production unit equipped to produce solid oral dosage forms including tablets (1,200 million units/year), dry syrups (3 million units/year), and liquid syrups (10 million units/year). Features 2 granulation rooms (one with explosion-proof system) and 2 compression rooms with high-capacity rotary tablet presses. Designed for WHO GMP compliance and serves as the primary unit for general therapeutic generic medicines.
  • Antibiotiques Bétalactamines (Beta-lactam Antibiotics Unit) Dedicated beta-lactam antibiotic production unit with fully segregated facilities, equipment, personnel, water treatment, air handling, and a dedicated quality control laboratory. Production capacity of 280 million tablets and 56 million capsules per year. Includes dedicated changing rooms with air shower exit system and special air treatment with water purification to prevent cross-contamination.
  • Solutés massifs (Large Volume Parenteral Solutions Unit) Large volume parenteral solutions (IV fluids) production unit with installed capacity of 10 million 250ml and 500ml flasks per year using BFS (Blow-Fill-Seal) technology with pharmaceutical grade B and A zone filling. Features stainless steel 316L tanks, 2-micron and 0.22-micron filtration, nitrogen pressure transfer, and autoclave sterilization for injectable-grade solutions.
  • Médicaments Génériques (Generic Medicines Portfolio) Portfolio of approximately 60 pharmaceutical molecules producing a varied range of generic essential medicines (MEG) adapted to African public health challenges and emerging pandemics. Therapeutic focus areas include malaria, HIV/AIDS, and tuberculosis treatments, with products manufactured across all three CINPHARM production units in various dosage forms.
  • Licensed Manufacturing Partnerships (Technology Transfer Platform) Open partnership platform offering international pharmaceutical laboratories technology transfer and licensed manufacturing services using CINPHARM's GMP-compliant facilities and expertise. Designed to enable international partners to manufacture medications under license for African markets, leveraging CINPHARM's WHO GMP certification and quality infrastructure.

Companies that use CINPHARM SA

Customer profile

Segments3 records

Ideal customer profiles3 records

CINPHARM SA technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

CINPHARM SA partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and supporting.

  • CADYST-InvestcoreOthers · 1 January 2007CADYST-Invest is the parent industrial group that acquired CINPHARM as a subsidiary in 2007. The group provided the vision and investment strength for establishing the pharmaceutical manufacturing facility in Cameroon.
  • UNIDO (Onudi)coreImplementation/ SI/ Consulting PartnerThe United Nations Industrial Development Organization contributed to the training of CINPHARM's collaborators, supporting capacity building for pharmaceutical manufacturing expertise.
  • Republic of CamerooncoreStrategic or Co-development PartnerThe Cameroon government supported and facilitated CINPHARM's investment program. CINPHARM serves as an implementation tool for the government's public health policy.
  • CiplacoreTechnology or IntegrationIndian pharmaceutical company Cipla provides technology transfer and training to CINPHARM, enabling the development of pharmaceutical manufacturing capabilities.
  • Fondation ChiracsupportingStrategic or Co-development PartnerThe scientific committee is sponsored by Pr Gentilini of the Fondation Chirac. Pr Gentilini served as President of the French Red Cross and General Delegate for access to quality medicines at Fondation Chirac.

Scale indicators7 records

Recent moves6 records

Expansion highlights4 records

CINPHARM SA competitors and assessment

Company assessment

Broad incumbents

  • Sanofi: Global pharmaceutical major with significant African generics and vaccines presence via its Sanofi Global Health unit. Important adjacent incumbent shaping African essential medicines tenders and partnership opportunities relevant to CINPHARM's licensing model.
  • Emcure Pharmaceuticals: Indian global generic pharmaceutical manufacturer with significant emerging markets and Africa exposure across antimalarials, ARVs, and essential medicines. Comparable high-volume low-cost generic business model targeting African and other emerging market tenders.
  • Aspen Pharmacare: Largest African pharmaceutical manufacturer, headquartered in South Africa, with broad generic essential medicines, ARVs, and sterile manufacturing capacity. Aspirational reference peer for CINPHARM's ambition to be the reference pharma lab in Sub-Saharan Africa.
  • Strides Pharma Science Limited: Indian global generic pharmaceutical company with strong Africa-focused ARV and essential medicines franchise and WHO prequalifications. Closely mirrors CINPHARM's product focus and partnership-style business model.
  • Cipla: Indian global generic pharmaceutical major and CINPHARM's explicit technology transfer partner. Cipla is the most directly comparable peer as a high-volume, low-cost generic manufacturer with deep Africa exposure — the very model CINPHARM emulates at smaller scale.

Regional players

  • Fidson Healthcare Plc: Nigeria-listed pharmaceutical manufacturer producing generic essential medicines across therapeutic categories with multiple production lines. Comparable as a West/Central African local generic manufacturer competing for similar public-sector and regional tenders.
  • May & Baker Nigeria Plc: Nigerian pharmaceutical manufacturer with diversified generic essential medicines portfolio across tablets, capsules, syrups, and injectables. Regional West African peer with similar scale, multi-unit production, and public-sector tender focus.
  • Universal Corporation Ltd: Kenyan pharmaceutical manufacturer producing generic essential medicines, antimalarials, and ARVs for East African markets. Regional African generic manufacturer with similar scale, product breadth, and WHO-aligned positioning as CINPHARM.
  • Addis Pharmaceutical Factory: Ethiopian state-affiliated generic pharmaceutical manufacturer producing essential medicines for domestic and export markets. Comparable as an African local generic manufacturer serving a domestic public health mandate with multiple production units.

Direct peers

  • Quality Chemical Industries Limited: Uganda-based WHO-prequalified generic pharmaceutical manufacturer, also established with Cipla technology transfer and donor-aligned product portfolio (including antimalarials and ARVs). CINPHARM's closest structural peer in East/Central Africa in terms of origin story, partnership model, and product focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

CINPHARM SA social profiles

Digital presence

CINPHARM SA compliance and trust

Trust signal

Compliance2 records

CINPHARM SA financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CINPHARM SA leadership team

Management profile

Number of profiles

Profiles1 record

CINPHARM SA funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CINPHARM SA M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CINPHARM SA

What does CINPHARM SA do?

CINPHARM manufactures generic essential medicines (médicaments essentiels génériques — MEG) targeting malaria, HIV/AIDS, and tuberculosis through three distinct WHO GMP-compliant production units: Formulation Générale (tablets, capsules, syrups), Antibiotiques Bétalactamines (dedicated beta-lactam facility), and Solutés massifs (large volume IV solutions via BFS technology). Beyond manufacturing its own ~60-molecule portfolio, the company operates as an open platform offering technology transfer and licensed contract manufacturing for international pharmaceutical laboratories.

Is CINPHARM SA a public or private company?

CINPHARM SA is a private company. It is classified as corporate owned and is currently operating.

When was CINPHARM SA founded?

CINPHARM SA was founded in 2006. It employs 51 to 100 people.

Where is CINPHARM SA based?

CINPHARM SA is headquartered in Douala, Cameroon, in the Africa region.

How does CINPHARM SA make money?

Two revenue lines are on record. Generic Pharmaceutical Products are the primary driver. The others are licensed Manufacturing Partnerships.

Who are CINPHARM SA's main competitors?

Broad incumbents on record are Sanofi, Emcure Pharmaceuticals, Aspen Pharmacare, Strides Pharma Science Limited and Cipla. Regional players are Fidson Healthcare Plc, May & Baker Nigeria Plc, Universal Corporation Ltd and Addis Pharmaceutical Factory. Quality Chemical Industries Limited is listed as a direct peer.

Does CINPHARM SA have an API?

No public API is recorded for CINPHARM SA.

What industry is CINPHARM SA in?

CINPHARM SA's product category is Generic Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIABAI, Contract Development & Manufacturing for Generics (CDMO/CMO), with a secondary code of HLAGAGAL, GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales